Leucemia aguda linfoblástica: de la aminopterina a las células CAR T

Ribera Santasusana, Josep-Maria.
Med. clín (Ed. impr.) ; 154(7): 269-274, abr. 2020. graf, tab
Artículo en Español | IBECS (España) | ID: ibc-190911

Documentos relacionados

  1. CD19 CAR T Cells.
  2. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel.
  3. Modulation of CD19 surface expression in B cell acute lymphoblastic leukemia.
  4. Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series.
  5. A systematic review on the cost-effectiveness assessment of tisagenlecleucel for refractory or relapsing B-cell acute lymphoblastic leukemia (R/R B-ALL) treatment in children and young adults.
  6. Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel.
  7. [Recent research on chimeric antigen receptor T cells in children with refractory/relapsed acute lymphoblastic leukemia].
  8. Genetic Profiling in Children With Acute Lymphoblastic Leukemia Referred for Allogeneic Hematopoietic Stem Cell Transplantation.
  9. Single-cell analysis of acute lymphoblastic and lineage-ambiguous leukemia: approaches and molecular insights.
  10. The Philadelphia Chromosome, from Negative to Positive: A Case Report of Relapsed Acute Lymphoblastic Leukemia Following Allogeneic Stem Cell Transplantation.